Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Opinion & analysis

Opinion & analysis


  • Sort by Custom
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • The Gene Therapies Are Coming – And So Are New Ways To Pay For Them

    $200.00

    At the 2019 J.P. Morgan Healthcare Conference, bluebird bio Inc. became the first company to propose a 5-year annual installment payment plan for its gene therapy Lentiglobin, the first such payment plan proposal of its kind. Hear more about the reaction to the proposal from other pharma players and from insurers in this informative Scrip article.

    January 15, 2019
    Find out more
  • The Implant Files: EU Blamed For Regulatory Inadequacies The World Over While ‘Wrath’- Behrendt Fumes

    $131.00

    In the wake of scathing investigative reports from over 250 journalists from the International Consortium of Investigative Journalists (ICIJ) regarding the safety and oversight of implanted medical devices, this article examines the situation from a uniquely EU perspective.

    November 26, 2018
    Find out more
  • The Intersection Between Tech and Pharma Special Report (Part 2. Apple)

    $3,000.00

    In January 2015, Fortune reported that at $2.9tn, the state of the US healthcare industry is very strong and continues to grow. Additionally, a Top Issues report revealed that 40% of Fortune 50 companies pursued new healthcare partnerships in 2014. Given the rapid change in the healthcare industry over the last few years, it is no surprise that we are starting to see more non-traditional healthcare partnerships, specifically with big tech companies.

    January 14, 2016
    Find out more
  • The Intersection Between Tech and Pharma Special Report (Part 3. Intel, Samsung, IBM, and GE)

    $3,000.00

    The Intersection Between Tech and Pharma Special Report (Part 3. Intel, Samsung, IBM, and GE)

    January 22, 2016
    Find out more
  • The Knowledge Within: An Interview With Merck KGaA’s R&D Chief

    $200.00

    Merck KGaA’s head of global research and development, Luciano Rossetti, sat down with In Vivo to discuss the track the German company is taking toward becoming a major player in global immuno-oncology. Tap in to his insights and opinions in this essential interview.

    March 11, 2019
    Find out more
  • The Next New Thing In FDA Inspections: Poor Root Cause Investigations

    $131.00

    As the pharmaceuticals industry gets its issues with data integrity under control, a new challenge has arisen, according to US FDA comments at a recent meeting of the International Society for Pharmaceutical Engineering. Find out how these out-of-specification investigation (OOS) issues are playing out, with expert reporting from Pink Sheet.

    January 6, 2019
    Find out more
  • The Oncology Burden Of Proof: Learning From The PD-1 Market

    $200.00

    In Vivo interviews Eva Marchese, VP at consulting group Charles River Associates, for insights into the challenges facing the PD-1/LD1 European market’s reimbursement and access schemes for IO products. Gain insights into the sustainability obstacles for immuno-oncology products in this vital interview.

    November 7, 2018
    Find out more
  • Thinking about using CMMI? Here are tips from the experts

    $200.00

    Learn about the voluntary U.S. FDA pilot program that uses Capability Maturity Model Integration (CMMI) from quality,compliance and regulatory officials at three major device firms. Walk through the CMMI process,and discover why it’s nothing like a typical regulatory audit.

    June 25, 2018
    Find out more
  • Top 10 Drugs: Biologic Blockbusters And The Biosimilar Threat

    $131.00

    Pharma companies faced a “patent cliff” a decade ago with generic competition threatening to slash sales of certain blockbusters. The new threat is biosimilars. Scrip shows how some mature cancer and autoimmune biologics are still the major drivers of revenues, and how biosimilars are gaining on them.

    August 9, 2019
    Find out more
  • Top 10 Drugs: Weighing Pharma’s Golden Eggs

    $131.00

    A relatively small number of costly drugs account for a sizable portion of pharma industry revenues. This informative and easily scannable Scrip infographic shows which drugs are the golden eggs, which companies are behind them, and how the landscape has changed in the past decade.

    August 6, 2019
    Find out more
  • Top 10 Most Read Stories Of 2018

    $131.00

    Find out which stories captured the attention of In Vivo readers last year, with In Vivo’s annual list of most-read articles. This top-ten list offers a glimpse into the issues, events, and trends that mattered most to In Vivo readers in 2018.

    January 2, 2019
    Find out more
  • Top 20 Pharma Ranks: As Some Move Up, Others Fall Down

    $131.00

    Although the ranking of Scrip’s top 100 pharma companies remained largely the same as the previous year, there were some surprising moves up – and down – in rank for major players within pharma. Find out who in the top 20 moved, and in what direction, in this essential resource from In Vivo.

    December 13, 2018
    Find out more
  • Transforming Pharmaceutical R&D with Data

    Transforming Pharmaceutical R&D with Data

    $2,995.00

    Ongoing pressures on drug pricing and reimbursement mean that current research and development (R&D) economics are unsustainable.  The process of discovering and developing a drug has not fundamentally changed for decades, and on average it still costs $2.6bn and takes over 10 years. Fortunately, tools are emerging to help improve R&D success rates. Most are built on better use of more kinds of data, including using artificial intelligence (AI) to process massive quantities of information that humans cannot manage. Some of these new tools promise cost and time savings of between 20–50%

    May 2, 2017
    Find out more
  • Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

    $200.00

    The Trump Administration’s “Blueprint to Lower Prices and Reduce Out-of-Pocket Costs” includes dramatic changes to protected classes, rebates and PBM reimbursement. Discover why the blueprint has industry leaders worried. Explore the implications for biopharmas and PBMs in particular and the healthcare industry in general.

    May 11, 2018
    Find out more
  • Trump’s Drug Pricing ‘Dream Team’ And Prospects For Change

    $131.00

    The US Department of Health and Human Services is hoping for stability in its ranks in order to move its drug pricing reform policy forward, according to HHS Deputy Secretary Eric Hargan. Find out more about anticipated personnel adjustments to the HHS in this Pink Sheet article.

    November 24, 2018
    Find out more
Page 18 of 20
Page 18 of 20«‹1617181920›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top